脑组织氧联合颅内压/脑灌注压导向治疗与颅内压/脑灌注压导向治疗在创伤性脑损伤中的死亡率和结局比较:一项Meta分析
该系统评价于2016年7月检索多个数据库,纳入8项队列研究和1项随机对照试验,比较脑组织氧联合颅内压/脑灌注压导向治疗与标准颅内压/脑灌注压导向治疗对创伤性脑损伤患者死亡率和结局的影响。结果显示联合治疗组6个月内获得良好结局的可能性更高(RR 1.26,95%CI 1.04-1.52),但死亡率、颅内压、脑灌注压和住院时间无显著差异。
要点
- 联合治疗组6个月内良好结局的可能性高于标准治疗组(RR 1.26,95%CI 1.04-1.52)。
- 两组总体死亡率、出院死亡率和3个月死亡率均无显著差异。
- 两组颅内压、脑灌注压和住院时间均无显著差异。
核心结论
- 与标准颅内压/脑灌注压导向治疗相比,脑组织氧联合颅内压/脑灌注压导向治疗改善了长期结局,对死亡率、颅内压/脑灌注压或住院时间无影响。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library、ClinicalTrials.gov和Web of Science(2016年7月),纳入8项队列研究和1项随机对照试验。
主要发现
- 联合治疗组与标准治疗组总体死亡率风险比无显著差异(RR 0.76,95%CI 0.54-1.06)。
- 出院死亡率无显著差异(RR 1.01,95%CI 0.80-1.26),3个月死亡率无显著差异(RR 0.77,95%CI 0.53-1.12)。
- 联合治疗组6个月内良好结局可能性更高(RR 1.26,95%CI 1.04-1.52),恰好6个月时良好结局可能性更高(RR 1.34,95%CI 1.07-1.68)。
- 两组颅内压(SMD -0.19,95%CI -0.43至0.05)、脑灌注压(SMD 0.13,95%CI -0.09至0.35)和住院时间(SMD 0.13,95%CI -0.11至0.37)均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of brain tissue oxygen and standard intracranial pressure (ICP)/cerebral perfusion pressure (CPP)-guided therapy is thought to improve traumatic brain injury (TBI) prognosis compared with standard ICP/CPP-guided therapy. However, related results of previous observational studies and recently published cohort studies and randomized controlled trials (RCTs) remain controversial. The objective of this study was to compare the effect of the combined therapy with that of standard ICP/CPP-guided therapy on mortality rate, favorable outcome, ICP/CPP, and length of stay (LOS). METHODS: We systematically searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and Web of Science in July 2016 for studies comparing the combined therapy and standard ICP/CPP-guided therapy. Random-effect and fixed-effect models were used for pooled analyses. RESULTS: After screening 362 studies, 8 cohort studies and 1 RCT were included. Primary outcomes were mortality and favorable outcome. The overall mortality risk ratio showed no obvious advantages between the 2 groups (risk ratio [RR], 0.76; 95% confidence interval [CI], 0.54-1.06) and discharge mortality (RR, 1.01; 95% CI, 0.80-1.26) and 3-month mortality (RR, 0.77; 95% CI, 0.53-1.12). Compared with the ICP/CPP group, the combined group was more likely to achieve better outcome during the 6 months after TBI (RR, 1.26; 95% CI, 1.04-1.52) or exactly at 6 months (RR, 1.34; 95% CI, 1.07-1.68), whereas ICP (standardized mean difference [SMD], -0.19; 95% CI, -0.43 to 0.05), CPP (SMD, 0.13; 95% CI, -0.09 to 0.35), and LOS (SMD, 0.13; 95% CI, -0.11 to 0.37) showed no obvious differences. CONCLUSIONS: Compared with standard ICP/CPP-guided therapy, brain tissue oxygen combined with ICP/CPP-guided therapy improved long-term outcomes without any effects on mortality, ICP/CPP, or LOS.
引用
- Xie Q, Wu HB, Yan YF, et al. Mortality and Outcome Comparison Between Brain Tissue Oxygen Combined with Intracranial Pressure/Cerebral Perfusion Pressure-Guided Therapy and Intracranial Pressure/Cerebral Perfusion Pressure-Guided Therapy in Traumatic Brain Injury: A Meta-Analysis. World Neurosurg. 2017. PMID: 28057593. doi:10.1016/j.wneu.2016.12.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。